ライフサイエンスコーパス: retinopathy of prematurity

1 omplications, bronchopulmonary dysplasia, or retinopathy of prematurity).

2 like proliferative diabetic retinopathy and retinopathy of prematurity.

3 ent, cognitive or language delay, and severe retinopathy of prematurity.

4 periventricular leukomalacia, and/or severe retinopathy of prematurity.

5 lasia, necrotizing enterocolitis, and severe retinopathy of prematurity.

6 retinopathy that is representative of human retinopathy of prematurity.

7 iretinal membranes, retinal detachments, and retinopathy of prematurity.

8 rescein angiograms in premature infants with retinopathy of prematurity.

9 etinal vasculature in premature infants with retinopathy of prematurity.

10 l ulceration, cytomegalovirus retinitis, and retinopathy of prematurity.

11 wide-angle retinal images from infants with retinopathy of prematurity.

12 dysplasia, periventricular leucomalacia, and retinopathy of prematurity.

13 mia in diabetes, retinal vein occlusion, and retinopathy of prematurity.

14 nd intravitreal neovascularization (IVNV) in retinopathy of prematurity.

15 out inhibiting its activity to treat IVNV in retinopathy of prematurity.

16 r stage 3+ (i.e., stage 3 with plus disease) retinopathy of prematurity.

17 means for screening diabetic retinopathy and retinopathy of prematurity.

18 e diseases, such as diabetic retinopathy and retinopathy of prematurity.

19 that these agents may be useful in treating retinopathy of prematurity.

20 nal human/murine blood vessel formation, and retinopathy of prematurity.

21 tic retinopathy, retinal vein occlusion, and retinopathy of prematurity.

22 itamin A deficiency, congenital cataract and retinopathy of prematurity.

23 an adjunct to laser for aggressive posterior retinopathy of prematurity.

24 the pathogenesis of many diseases including retinopathy of prematurity.

25 the use of adjuncts for aggressive posterior retinopathy of prematurity.

26 s of the retina in a standard mouse model of retinopathy of prematurity.

27 ghest risk for developing complications from retinopathy of prematurity.

28 ngoing retinal vascular development, such as retinopathy of prematurity.

29 the catastrophic vessel loss that initiates retinopathy of prematurity.

30 larization, such as diabetic retinopathy and retinopathy of prematurity.

31 ve deleterious, protective, and no effect on retinopathy of prematurity.

32 in the multicenter study of Cryotherapy for Retinopathy of Prematurity.

33 ng has been suggested as a factor in causing retinopathy of prematurity.

34 ght exposure does not alter the incidence of retinopathy of prematurity.

35 hemorrhages, and 2 were diagnosed as having retinopathy of prematurity.

36 nt in proliferative retinopathies, including retinopathy of prematurity.

37 rate-severe chronic lung disease, and severe retinopathy of prematurity.

38 chronic lung disease, and stage 3 or higher retinopathy of prematurity.

39 for oxygen saturation had a reduced rate of retinopathy of prematurity (10.6% vs. 13.5%; relative ri

40 n were traumatic ocular injury (15 [22.1%]), retinopathy of prematurity (12 [17.6%]), and endophthalm

41 athy (OIR) is a well-characterized model for retinopathy of prematurity, a disorder that results from

42 In a mouse model for retinopathy of prematurity, adam15(-/-) mice had a major

43 Retinopathy of prematurity adversely affects premature i

44 vent all vision loss, especially in cases of retinopathy of prematurity affecting zone I of the eye.

45 dative age-related macular degeneration, and retinopathy of prematurity, among others.

46 c vitrectomy; (5) treatment of proliferative retinopathy of prematurity and (6) treatment of retinal

47 Secondary outcomes included retinopathy of prematurity and brain injury.

48 ss associated with ischemic diseases such as retinopathy of prematurity and diabetic retinopathy are

49 Ischemic retinopathies, including retinopathy of prematurity and diabetic retinopathy, are

50 These diseases include retinopathy of prematurity and diabetic retinopathy, lea

51 g the progression of ocular diseases such as retinopathy of prematurity and diabetic retinopathy, ove

52 stating ischemia of many diseases, including retinopathy of prematurity and diabetic retinopathy.

53 are associated with retinal diseases such as retinopathy of prematurity and diabetic retinopathy.

54 might accelerate tissue revascularization in retinopathy of prematurity and in diabetic patients.

55 Small studies show an association between retinopathy of prematurity and later retinal detachment.

56 he mechanisms that underlie the formation of retinopathy of prematurity and related detachments is no

57 the factors involved in the pathogenesis of retinopathy of prematurity and related retinal detachmen

58 e the rate from the best quartile for severe retinopathy of prematurity and severe intraventricular h

59 Surgery for retinopathy of prematurity and surgery for necrotizing e

60 ment concepts for diagnosis and treatment of retinopathy of prematurity and to provide interpretation

61 role in screening for diabetic retinopathy, retinopathy of prematurity, and age-related macular dege

62 in conditions such as diabetic retinopathy, retinopathy of prematurity, and age-related macular dege

63 ion of the visual system, the development of retinopathy of prematurity, and ametropia.

64 ar hemorrhage, periventricular leucomalacia, retinopathy of prematurity, and bronchopulmonary dysplas

65 such as for diabetic retinopathy, threshold retinopathy of prematurity, and exudative macular degene

66 nship between bronchopulmonary dysplasia and retinopathy of prematurity, and may form a bridge betwee

67 (prevalence, <1%) including cardiomyopathy, retinopathy of prematurity, and neonatal thyroid disease

68 ing conditions such as diabetic retinopathy, retinopathy of prematurity, and neovascular glaucoma.

69 eneration, retinal venous occlusive disease, retinopathy of prematurity, and optical aberrations incl

70 hage, necrotizing enterocolitis, aspiration, retinopathy of prematurity, and perinatal mortality.

71 monary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, and severe intraventricular

72 otizing enterocolitis, or stage 3 or greater retinopathy of prematurity; and severe neonatal brain in

73 f life; advancements in the understanding of retinopathy of prematurity; and understanding the develo

74 ry (AOR, 0.80; 95% CI, 0.63-1.01), or severe retinopathy of prematurity (AOR, 0.78; 95% CI, 0.56-1.10

75 4; 95% CI, 1.87-2.21), and stage 3 or higher retinopathy of prematurity (aOR, 1.18; 95% CI, 1.06-1.32

76 ase (aOR, 1.36; 95% CI, 0.78-2.39) or severe retinopathy of prematurity (aOR, 1.61; 95% CI, 0.85-3.06

77 ) fibrous membranes, or aggressive posterior retinopathy of prematurity (AP-ROP).

78 Goals for retinopathy of prematurity are to optimize prenatal and

79 ays that cause pathologic features in severe retinopathy of prematurity as it manifests in the era of

80 tamin A deficiency, perinatal infections and retinopathy of prematurity as well as specialist pediatr

81 eatment assignments assessed the infants for retinopathy of prematurity at least biweekly for up to 1

82 ined in 3 consecutive premature infants with retinopathy of prematurity at the Oxford Eye Hospital, O

83 the therapeutic value of HIF PHDi to prevent retinopathy of prematurity because it reduces oxygen-ind

84 dities, including necrotizing enterocolitis, retinopathy of prematurity, bronchopulmonary dysplasia,

85 associated with serious morbidities such as retinopathy of prematurity, bronchopulmonary dysplasia,

86 ries, and increasing morbidity count (severe retinopathy of prematurity, bronchopulmonary dysplasia,

87 strabismus, optic neuropathy, nystagmus, or retinopathy of prematurity) by ICD-9 codes in typically

88 In retinopathy of prematurity, capillary growth in the reti

89 nibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) randomized clinica

90 The Children's Hospital of Philadelphia Retinopathy of Prematurity (CHOP ROP) model uses birth w

91 and The Children's Hospital of Philadelphia Retinopathy of Prematurity (CHOP-ROP) postnatal weight g

92 The surgical management of retinopathy of prematurity continues to employ a paradig

93 nd techniques for the surgical management of retinopathy of prematurity continues to evolve and outco

94 Analysis of data from the Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) and Early Treatmen

95 The overall goal is to clarify retinopathy of prematurity currently and formulate quest

96 We also review the applications to retinopathy of prematurity, diabetic retinopathy, age-re

97 Neovascular eye diseases, including retinopathy of prematurity, diabetic retinopathy, and ag

98 many vision-threatening diseases, including retinopathy of prematurity, diabetic retinopathy, and ag

99 tigating the utility of anti-VEGF therapy in retinopathy of prematurity, diabetic retinopathy, and ne

100 Worldwide, retinopathy of prematurity differs and, in emerging coun

101 in children who developed only mild forms of retinopathy of prematurity during early life.

102 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) Study and to evaluate

103 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) Study telemedicine sy

104 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity (e-ROP) study was conducted f

105 Approaches for the Evaluation of Acute-Phase Retinopathy of Prematurity (e-ROP) study.

106 ematurity (CRYO-ROP) and Early Treatment for Retinopathy of Prematurity (ETROP) trials and the primar

107 iabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exudative age-related macula

108 o that experienced in the United States when retinopathy of prematurity first manifested.

109 s has been implicated in the pathogenesis of retinopathy of prematurity for decades.

110 medicine study) and the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study (a multicenter

111 alysis of data from the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study.

112 Retinopathy of prematurity has evolved from affecting in

113 ho undergo early screening and treatment for retinopathy of prematurity have improved long-term funct

114 52% of treated eyes with retinopathy of prematurity in a multicenter cohort didn'

115 The primary ocular outcome was recurrence of retinopathy of prematurity in one or both eyes requiring

116 A significant decrease in rates of retinopathy of prematurity in our post-intervention grou

117 There was no association with retinopathy of prematurity in the preterm group, which s

118 the ffERG recordings and gestational age or retinopathy of prematurity in the preterm group.

119 fferences between the groups in the rates of retinopathy of prematurity, intracranial hemorrhage, sep

120 Retinopathy of prematurity is a disease that manifests s

121 Retinopathy of prematurity is a leading cause of childho

122 Retinopathy of prematurity is a leading cause of childho

123 Retinopathy of prematurity is a major side effect of oxy

124 Retinopathy of prematurity is a sight-threatening compli

125 s improve the survival of premature infants, retinopathy of prematurity is emerging as a significant

126 Retinopathy of prematurity is located asymmetrically aro

127 Retinopathy of prematurity is the leading cause of child

128 gy of proliferative diabetic retinopathy and retinopathy of prematurity is the result of the ischemia

129 ne of the many controversies in the study of retinopathy of prematurity is whether hyperoxia or alter

130 opathy, age-related macular degeneration, or retinopathy of prematurity, is a leading cause of blindn

131 the mouse, like the analogous human disease retinopathy of prematurity, is an ischemic retinopathy d

132 the causative ischemia phase (hyperoxia) of retinopathy of prematurity may be of therapeutic value i

133 Older children with regressed retinopathy of prematurity may suffer from vitreous hemo

134 ocked down Muller cell-expressed VEGF in the retinopathy of prematurity model also reduced phosphoryl

135 newborn, such as bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, a

136 injury on postnatal ultrasonography, severe retinopathy of prematurity, necrotizing enterocolitis, o

137 ty at 24 months, bronchopulmonary dysplasia, retinopathy of prematurity, neurodevelopmental outcomes,

138 m, birth weight percentile, gestational age, retinopathy of prematurity occurrence, maternal age at c

139 th weight (VLBW) infants without significant retinopathy of prematurity or neurologic morbidities wer

140 macular degeneration, diabetic retinopathy, retinopathy of prematurity, or as a complication followi

141 were no differences in chronic lung disease, retinopathy of prematurity, or NDI among survivors.

142 ficant treatment effect was found for zone I retinopathy of prematurity (P=0.003) but not for zone II

143 In the oxygen-induced retinopathy model of retinopathy of prematurity, PGC-1alpha expression is dra

144 udies included low birth weight, cicatricial retinopathy of prematurity, prematurity, smoking through

145 ) has been widely used in studies related to retinopathy of prematurity, proliferative diabetic retin

146 tion underlies blinding eye diseases such as retinopathy of prematurity, proliferative diabetic retin

147 Retinopathy of prematurity recurred in 3 (14%) of 22 IVB

148 Retinopathy of prematurity recurred in 4 infants in the

149 Patients undergoing surgical repair of retinopathy of prematurity-related detachments (stage 4A

150 patent ductus arteriosus requiring surgery, retinopathy of prematurity requiring surgery, necrotizin

151 Cases involving retinopathy of prematurity resulted in the highest payme

152 s were grouped as those who were treated for retinopathy of prematurity (ROP) (ROP-Tx group); those w

153 Retinopathy of prematurity (ROP) affects only premature

154 increased neovascularization in the model of retinopathy of prematurity (ROP) and in the in vivo Matr

155 Because angiogenic abnormalities in retinopathy of prematurity (ROP) are manifested in prete

156 Bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) are two debilitating di

157 of intravitreal bevacizumab (IVB) for type 1 retinopathy of prematurity (ROP) are uncertain.

158 al weight gain are known predictors of worse retinopathy of prematurity (ROP) but the role of prenata

159 l trends in the diagnosis of plus disease in retinopathy of prematurity (ROP) by experts.

160 eveloped to improve diagnostic competency in retinopathy of prematurity (ROP) by ophthalmologists-in-

161 tinopathy (OIR) was generated as a model for retinopathy of prematurity (ROP) by placing 7-day-old mi

162 Regular retinal evaluation is necessary for retinopathy of prematurity (ROP) cases.

163 Retinopathy of prematurity (ROP) caused blindness in 32.

164 Retinopathy of prematurity (ROP) causes 100,000 new case

165 th factor (VEGF) agents for the treatment of retinopathy of prematurity (ROP) compared with laser pho

166 ances in neonatal and ophthalmological care, retinopathy of prematurity (ROP) continues to be a leadi

167 on retinal image grading of fellow eyes for retinopathy of prematurity (ROP) features (stage, zone a

168 endothelial growth factor (VEGF) therapy for retinopathy of prematurity (ROP) has potential ocular an

169 Telemedicine in retinopathy of prematurity (ROP) has the potential for d

170 ffective treatments for potentially blinding retinopathy of prematurity (ROP) have been introduced, t

171 Detection of treatment-requiring retinopathy of prematurity (ROP) involves serial eye exa

172 Retinopathy of prematurity (ROP) is a leading cause of b

173 Retinopathy of prematurity (ROP) is a leading cause of c

174 Retinopathy of prematurity (ROP) is a major complication

175 Retinopathy of prematurity (ROP) is a potentially blindi

176 Severe Retinopathy of Prematurity (ROP) is a serious vasoprolif

177 Retinopathy of prematurity (ROP) is a vision-threatening

178 ndirect ophthalmoscopy (BIO) examination for retinopathy of prematurity (ROP) is a well-known cause o

179 Retinopathy of prematurity (ROP) is characterized by an

180 Accurate diagnosis of retinopathy of prematurity (ROP) is essential to provide

181 reduced vision in patients with a history of retinopathy of prematurity (ROP) is not yet fully unders

182 Retinopathy of prematurity (ROP) is one of the targets f

183 Retinopathy of prematurity (ROP) is the leading cause of

184 f visual impairment/blindness as a result of retinopathy of prematurity (ROP) may rise.

185 A murine retinopathy of prematurity (ROP) model was used to exami

186 n profile of the miR-17 family in the murine retinopathy of prematurity (ROP) model, whereby Vegfa ex

187 Children born prematurely who develop retinopathy of prematurity (ROP) often develop myopia, a

188 685 patients, including 8 cases of bilateral retinopathy of prematurity (ROP) received RLT.

189 Published definitions of plus disease in retinopathy of prematurity (ROP) reference arterial tort

190 ibed, the putative roles of these factors in retinopathy of prematurity (ROP) remain unknown.

191 Despite current treatments, retinopathy of prematurity (ROP) remains a major cause o

192 gy to identify infants needing treatment for retinopathy of prematurity (ROP) requires repeated exami

193 r pigment in premature babies at the time of retinopathy of prematurity (ROP) screening and in childr

194 atics administered in preterm infants during retinopathy of prematurity (ROP) screening have been ass

195 Artificial intelligence (AI)-based retinopathy of prematurity (ROP) screening may improve R

196 17 4-8 year olds with a history of retinopathy of prematurity (ROP) screening were recruite

197 andheld ophthalmologic equipment used during retinopathy of prematurity (ROP) screening.

198 undred thirty-one preterm infants undergoing retinopathy of prematurity (ROP) screenings.

199 Currently used screening criteria for retinopathy of prematurity (ROP) show high sensitivity f

200 Treatment of retinopathy of prematurity (ROP) stage 3 plus with bevac

201 elial growth factor (VEGF) in a patient with retinopathy of prematurity (ROP) treated with ranibizuma

202 isease between clinicians using an automated retinopathy of prematurity (ROP) vascular severity score

203 Retinal tissue from a mouse model of retinopathy of prematurity (ROP) was analyzed by RT-PCR

204 tyrosine kinase c-abl in the pathogenesis of retinopathy of prematurity (ROP) was examined using the

205 group of infants who underwent screening for Retinopathy of Prematurity (ROP) was obtained.

206 Screening for retinopathy of prematurity (ROP) was performed in the ne

207 In the 1940s and 1950s retinopathy of prematurity (ROP) was the single commones

208 A rat model of retinopathy of prematurity (ROP) was used in the in vivo

209 The neonatal mouse model of retinopathy of prematurity (ROP) was used to study the e

210 More severe stages of retinopathy of prematurity (ROP) were found among CMV-in

211 ctors, and with the presence and severity of retinopathy of prematurity (ROP) were investigated by un

212 (BRMECs) and a well-established rat model of retinopathy of prematurity (ROP) were used to investigat

213 Mouse models for retinopathy of prematurity (ROP) were used.

214 uld increase the quality of examinations for retinopathy of prematurity (ROP) while reducing neonatal

215 s a potentially more effective treatment for retinopathy of prematurity (ROP) with fewer acute and lo

216 were not previously diagnosed with neonatal retinopathy of prematurity (ROP), 38% of eyes (84) had R

217 he EP group, 48% of eyes (120 of 250) had no retinopathy of prematurity (ROP), 39% (98 of 250) had RO

218 In the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (ROP), 4099 infants weighing

219 scular damages are the cardinal hallmarks of retinopathy of prematurity (ROP), a leading cause of vis

220 Patients with PDR, retinopathy of prematurity (ROP), and wet age-related ma

221 gly important component of clinical care for retinopathy of prematurity (ROP), but little information

222 625 mg) is increasingly used to treat type 1 retinopathy of prematurity (ROP), but there remain conce

223 nt of several blinding retinopathies such as retinopathy of prematurity (ROP), diabetic retinopathy (

224 Many ocular pathologies, including retinopathy of prematurity (ROP), diabetic retinopathy,

225 ction development in children with regressed retinopathy of prematurity (ROP), including those with a

226 al disorders of retinal vasculature, such as retinopathy of prematurity (ROP), involve arrest or misp

227 or periventricular leukomalacia (PIVH/PVL), retinopathy of prematurity (ROP), length of hospital sta

228 oxygen-induced retinopathy (OIR) resembling retinopathy of prematurity (ROP), loss of Casp-8 in ECs

229 scularization in diabetic retinopathy and in retinopathy of prematurity (ROP), major causes of blindn

230 To test the hypothesis that in experimental retinopathy of prematurity (ROP), retinal neovasculariza

231 In children with a history of mild retinopathy of prematurity (ROP), test the hypothesis th

232 Retinopathy of prematurity (ROP), the most common cause

233 Retinopathy of prematurity (ROP), the primary cause of b

234 have been associated with the development of retinopathy of prematurity (ROP), the relationship betwe

235 In a rat model of retinopathy of prematurity (ROP), the retinal vasculatur

236 helial growth factor agents for treatment of retinopathy of prematurity (ROP), there are few data on

237 DIR) in the neonatal rat, analogous to human retinopathy of prematurity (ROP), was previously describ

238 This neovascularization appears analogous to retinopathy of prematurity (ROP), which occurs in human

239 actors, bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP), with cortical maturati

240 EGF Trap or hFc on P22 after confirmation of retinopathy of prematurity (ROP)-like pathology and were

241 tinal fundus images from infants at risk for retinopathy of prematurity (ROP).

242 n found to be effective for the treatment of retinopathy of prematurity (ROP).

243 ing and diagnostic tool in the management of retinopathy of prematurity (ROP).

244 d retinal detachment in preterm infants with retinopathy of prematurity (ROP).

245 vent neovascularization in a rodent model of retinopathy of prematurity (ROP).

246 ng in young-preterm infants without advanced retinopathy of prematurity (ROP).

247 d intravitreous neovascularization (IVNV) in retinopathy of prematurity (ROP).

248 atal weight gain is strongly associated with retinopathy of prematurity (ROP).

249 d review the recent scientific literature on retinopathy of prematurity (ROP).

250 acid (DHA) positively affect the outcome of retinopathy of prematurity (ROP).

251 rable than peripheral rods to the effects of retinopathy of prematurity (ROP).

252 ormalities that are the clinical hallmark of retinopathy of prematurity (ROP).

253 RTP801-knockout mice were used in a model of retinopathy of prematurity (ROP).

254 eovascularization (NV) in an animal model of retinopathy of prematurity (ROP).

255 es in basic science and clinical research on retinopathy of prematurity (ROP).

256 betic retinopathy, macular degeneration, and retinopathy of prematurity (ROP).

257 uced retinopathy which serves as a model for retinopathy of prematurity (ROP).

258 g to a vision-threatening retinopathy termed retinopathy of prematurity (ROP).

259 t retinas is analogous to clinically scoring retinopathy of prematurity (ROP).

260 : a retinal explant assay and a rat model of retinopathy of prematurity (ROP).

261 for the development of neovascularization in retinopathy of prematurity (ROP).

262 quantified and described in the dog model of retinopathy of prematurity (ROP).

263 ovascularization in the newborn rat model of retinopathy of prematurity (ROP).

264 thelial growth factor (VEGF) levels leads to retinopathy of prematurity (ROP).

265 sparing vitrectomy (LSV) surgery in advanced retinopathy of prematurity (ROP).

266 ight gain rate to predict the risk of severe retinopathy of prematurity (ROP).

267 optic components in children with or without retinopathy of prematurity (ROP).

268 f treatment strategies for the management of retinopathy of prematurity (ROP).

269 h conventional laser photoablation in type 1 retinopathy of prematurity (ROP).

270 icting associations between preeclampsia and retinopathy of prematurity (ROP).

271 iratory disorders, perinatal infections, and retinopathy of prematurity (ROP).

272 strongly associated with treatment-requiring retinopathy of prematurity (ROP).

273 pendent risk factors for treatment-demanding retinopathy of prematurity (ROP).

274 fection more than 3 days after birth, severe retinopathy of prematurity, severe intraventricular hemo

275 onal laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit

276 lar leukomalacia, necrotizing enterocolitis, retinopathy of prematurity stage 3-5, or severe bronchop

277 omalacia, severe bronchopulmonary dysplasia, retinopathy of prematurity (stage 3 or higher), or necro

278 ., before the national screening program for retinopathy of prematurity started), and 2 151 972 were

279 from the retrospective Postnatal Growth and Retinopathy of Prematurity Study (G-ROP) 1 study (2006-2

280 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity study, conducted from May 201

281 edicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity Study.

282 patients born after the Early Treatment for Retinopathy of Prematurity Study.

283 ased the prevalence of aggressive, posterior retinopathy of prematurity that may be unresponsive to c

284 C-A37668) was investigated in a rat model of retinopathy of prematurity, to examine the roles of MMP-

285 chalazion (one), corneal diameter (one), and retinopathy of prematurity (two).

286 Sensitivity for Early Treatment of Retinopathy of Prematurity type 1 ROP and potential redu

287 Retinopathy of prematurity was diagnosed in 102 infants

288 Retinopathy of prematurity was diagnosed in only two neo

289 The risk-adjusted probability of death or retinopathy of prematurity was highest among infants bor

290 28.4%) vs 126/485 (26.0%); and treatment for retinopathy of prematurity was required in 41/472 (8.7%)

291 al insufficiency (UPI) increases severity of retinopathy of prematurity, we developed a composite rat

292 OP and 14/55 (26%) with GA </= 32 weeks with retinopathy of prematurity were affected by strabismus.

293 their associations with gestational age and retinopathy of prematurity were examined.

294 urodevelopmental outcomes, hearing loss, and retinopathy of prematurity were similar between the 2 gr

295 have shown that infants had reduced rates of retinopathy of prematurity when lower targets of oxygen

296 ew intraretinal vessels in mouse OIR and rat retinopathy of prematurity, whereas preretinal vessels w

297 yndrome with cardiovascular development, and retinopathy of prematurity with lung development.

298 7 years old, 8 preterm and 17 with regressed retinopathy of prematurity with normal-appearing posteri

299 ose regarding pathophysiologic risk factors, retinopathy of prematurity worldwide, basic and clinical

300 hat characterizes severe treatment-requiring retinopathy of prematurity, yet diagnostic agreement amo